Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Fortress Biotech, Inc. amended Second Amendment to Credit Agreement with Oaktree Fund Administration, LLC valued at Amended credit agreement dated July 25, 2024; $35.0 million initial borrowing, up to $15.0 million a (effective 2026-02-22).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Oaktree Fund Administration, LLC
- Value
- Amended credit agreement dated July 25, 2024; $35.0 million initial borrowing, up to $15.0 million a
- Effective
- 2026-02-22
Exact text from the filing
On February 22, 2026, the Company, as borrower, entered into the Second Amendment to Credit Agreement (the “ Second Amendment ”), which amends that certain Credit Agreement dated July 25, 2024 (the “ Original Agreement ”) with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “ Agent ”), and the lenders from time to time party thereto (as amended by that certain First Amendment to Credit Agreement dated December 12, 2025, collectively with the Original Agreement and the Second Amendment, the “ Loan Agreement ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Fortress Biotech, Inc. entered into Priority Review Voucher Asset Purchase Agreement with Cyprium Therapeutics, Inc. valued at $205 million (effective 2026-02-22).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Cyprium Therapeutics, Inc.
- Value
- $205 million
- Effective
- 2026-02-22
Exact text from the filing
On February 22, 2026, Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (the “ Company ”), entered into a definitive asset purchase agreement (the “ PRV APA ”) pursuant to which Cyprium agreed to sell a Rare Pediatric Disease Priority Review Voucher (“ PRV ”).
View on SEC.gov